NeuroDerm has developed two doses of ND0612: the low-dose form is used to treat moderate stage Parkinson's patients who can no longer effectively control their motor complications with oral levodopa, and a higher dose for the treatment of severe Parkinson's patients for whom oral drugs are no longer effective.ND0612H was designed to be a safer, more effective and convenient alternative to ....